<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00050167</url>
  </required_header>
  <id_info>
    <org_study_id>ID01-580</org_study_id>
    <nct_id>NCT00050167</nct_id>
  </id_info>
  <brief_title>Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer</brief_title>
  <official_title>Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
        -  Determine the impact of each regimen on the disease free and overall survival of&#xD;
           patients with operable breast cancer.&#xD;
&#xD;
        -  Determine the ability of docetaxel/capecitabine to downstage primary breast cancer when&#xD;
           administered in the neoadjuvant setting when compared with weekly paclitaxel.&#xD;
&#xD;
        -  Determine the ability of each regimen to enhance breast conservation therapy when&#xD;
           administered in the neoadjuvant setting. (See protocol text for additional objectives&#xD;
           and details).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Before the study, participants will have a complete physical exam, including blood tests and&#xD;
      a chest x-ray. A mammogram and a sonogram of the breast and armpit will be done to record&#xD;
      tumor size (for patients who have not had surgery). Sonography of the liver or a CT scan of&#xD;
      the abdomen will also be done. In some patients who have not had surgery, 3-4 samples of the&#xD;
      breast tumor will be taken to help confirm the diagnosis of breast cancer. A biopsy needle&#xD;
      will be used to collect the samples.&#xD;
&#xD;
      During the study, participants will have blood tests done before each dose of chemotherapy.&#xD;
      For participants who have not had surgery, a mammogram and sonogram will be done of the&#xD;
      breast and armpit after completion of paclitaxel or docetaxel/capecitabine and after&#xD;
      completion of fluorouracil, cyclophosphamide, and epirubicin (FEC). These studies will help&#xD;
      doctors to keep track of the tumor size and help with the final decision whether to remove&#xD;
      all or part of the breast and nearby lymph nodes after completion of chemotherapy.&#xD;
&#xD;
      Participants in this study will be randomly assigned (as in the toss of a coin) to one of two&#xD;
      treatment groups. There is an equal chance of being in either group.&#xD;
&#xD;
      Participants in Group I will receive paclitaxel once a week. The drug will be given through a&#xD;
      plastic tube in a vein over 1 hour for a total of 12 treatments. Before each treatment,&#xD;
      patients will receive the drug Decadron (dexamethasone) through the vein and may receive&#xD;
      Zofran (ondansetron), Benadryl (diphenhydramine hydrochloride) and/or cimetidine to help&#xD;
      decrease the risk of side effects from paclitaxel.&#xD;
&#xD;
      Participants in Group II will receive docetaxel and capecitabine. Docetaxel will be given&#xD;
      once every 3 weeks. Docetaxel will be given through a plastic tube in the vein over 1 hour.&#xD;
      Capecitabine will be started the same day docetaxel is given. This medicine is given in a&#xD;
      pill form. The doctor will prescribe a dose of these pills based upon body weight and height.&#xD;
      Participants will take several pills two times a day for 14 days. Participants will then not&#xD;
      take any capecitabine pills for one week, until the next dose of docetaxel is given. This&#xD;
      combination of docetaxel and capecitabine will be given four times (over a period of 12&#xD;
      weeks). Before each treatment, patients will receive the drug Decadron (dexamethasone) by&#xD;
      mouth.&#xD;
&#xD;
      After treatment with either paclitaxel or docetaxel/capecitabine, all participants will&#xD;
      receive the drugs FEC through a plastic tube into a vein. All of these drugs will be given&#xD;
      once every three weeks for a total of 4 treatments (12 weeks total). Decadron&#xD;
      (dexamethasone), Zofran (ondansetron) and Benadryl (diphenhydramine hydrochloride) will be&#xD;
      given before the chemotherapy to help decrease the risk of side effects.&#xD;
&#xD;
      Participants who have a Her-2/neu positive cancer will potentially be eligible to receive&#xD;
      trastuzumab therapy for 1 year. This medicine is given through a vein either once a week&#xD;
      (over 30 minutes) or once every 3 weeks (over 30 minutes). Your doctor will discuss whether&#xD;
      this medicine is appropriate for you.&#xD;
&#xD;
      After all treatment is done, participants whose tumors are sensitive to hormones (estrogen)&#xD;
      will take a pill to help decrease the amount of hormone (estrogen) that can reach any tumor&#xD;
      cells. This pill will be taken once a day for 5 years.&#xD;
&#xD;
      Participants who have not completed surgery for their cancer before receiving the&#xD;
      chemotherapy described above will have surgery to remove all or part of the breast that has&#xD;
      cancer. If there are signs that the lymph nodes in the armpit (axilla) contain cancer, these&#xD;
      lymph nodes will also be removed.&#xD;
&#xD;
      After chemotherapy and surgery, or after completion of chemotherapy (patients who had surgery&#xD;
      done first), participants may then receive radiation treatment to the breast area and armpit&#xD;
      once a day (Monday through Friday) for 5-6 weeks.&#xD;
&#xD;
      After the study, participants will return for checkups every 3-4 months during Years 1 and 2,&#xD;
      every 6 months during years 3 and 4 and yearly after that. During the check-ups participants&#xD;
      will talk with and be examined by their physician. Once a year, patients will have yearly&#xD;
      mammograms (as needed), chest-x rays, and blood tests.&#xD;
&#xD;
      This is an investigational study. All of the drugs in this study are approved by the FDA for&#xD;
      treatment of breast cancer. A total of 930 patients will take part in this study. All will be&#xD;
      enrolled at M. D. Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Reoccurrence</measure>
    <time_frame>Median of 50 months</time_frame>
    <description>Percentage of participants where number with local recurrence, distant metastasis, or death of any cause at 50 months is divided by total number of participants and used as primary efficacy end point to compare paclitaxel to combination docetaxel and capecitabine in breast cancer treatment for preventing recurrence (return of cancer).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Pathological Complete Response</measure>
    <time_frame>7 Years</time_frame>
    <description>Safety of 2 Different Treatments determined by proportion of participants who achieved pathological complete response (pCR) between two different treatments; where pCR was defined as no histopathologic evidence of any residual invasive cancer cells in the breast and axillary lymph nodes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Effectiveness at Eradicating Tumor in the Breast and Lymph Nodes</measure>
    <time_frame>7 years</time_frame>
    <description>Effectiveness defined as proportion of patients who were able to have breast conserving surgery (BCS) after preoperative therapy compared to total number of participants.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly Paclitaxel (WP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weekly Paclitaxel (WP) for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel and Capecitabine (DX)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel + Capecitabine (DX) days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks</description>
    <arm_group_label>Weekly Paclitaxel (WP)</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks</description>
    <arm_group_label>Docetaxel and Capecitabine (DX)</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1500 mg/m^2 by mouth Twice Daily x 2 Weeks</description>
    <arm_group_label>Docetaxel and Capecitabine (DX)</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histologic confirmation of invasive, but non-inflammatory carcinoma of&#xD;
             the breast.&#xD;
&#xD;
          2. Stage I (T1N0) are not eligible for the neo-adjuvant portion of the protocol.&#xD;
&#xD;
          3. High-risk patients (patients with any of the following: high proliferation rate - Ki67&#xD;
             &gt;35% or poorly differentiated tumors (black's modified grade 3); ER/PR negative;&#xD;
             lymphovascular invasion) with stage I disease are eligible for adjuvant therapy.&#xD;
&#xD;
          4. Patients with pure mucinous carcinomas, tubular carcinomas or pure medullary&#xD;
             carcinomas are eligible if the patient's tumor is larger than 3 cm in size or if the&#xD;
             patient has tumor involvement of the lymph nodes (&gt;2mm).&#xD;
&#xD;
          5. Patients with bilateral breast cancers are eligible.&#xD;
&#xD;
          6. Patients with pN2a (metastasis in four to nine axillary lymph nodes) are eligible as&#xD;
             are patients with pN3a (ten or more axillary lymph nodes). Patients with&#xD;
             infraclavicular lymph node involvement are NOT eligible.&#xD;
&#xD;
          7. Patients must have clinically measurable disease to be treated in the neoadjuvant&#xD;
             setting. This includes patients with a non-palpable primary who have histologically&#xD;
             proven lymph node (LN) involvement that is clinically palpable and measurable by&#xD;
             ultrasound&#xD;
&#xD;
          8. Histologic confirmation of invasive tumor will be done by core needle biopsy for&#xD;
             patients with intact primary tumors. If patients have undergone adequate core biopsy&#xD;
             prior to evaluation at MDACC, repeat core biopsy is optional.&#xD;
&#xD;
          9. Patients must sign an informed consent indicating that they are aware of the&#xD;
             investigational nature of the study, in keeping with institutional policy.&#xD;
&#xD;
         10. Patients with a prior history of breast cancer are eligible if the current primary&#xD;
             breast cancer is of a higher stage than the original breast cancer and the patient has&#xD;
             not received any of the current study medications including past doxorubicin.&#xD;
&#xD;
         11. Patients should have adequate bone marrow function, as defined by peripheral&#xD;
             granulocyte count of &gt; 1,500/mm3, and platelet count &gt; 100,000/mm3. Patients must have&#xD;
             adequate liver function with a bilirubin within normal laboratory values.&#xD;
             Transaminases (SGPT) may be up to 2.5x upper limit of normal (ULN) if alkaline&#xD;
             phosphatase is &lt; ULN or alkaline phosphatase may be up to 4 x ULN if transaminases are&#xD;
             &lt; ULN.&#xD;
&#xD;
         12. In addition, patients should have adequate renal function, defined as a serum&#xD;
             creatinine &lt; 2.5 mg% and/or creatinine clearance greater than 51 ml/min as calculated&#xD;
             by Cockcroft and Gault Equation: Cockcroft and Gault Equation: Creatinine clearance&#xD;
             for males = {(140 - age [yrs])(body weight [kg])}/{(72) (serum creatinine [mg/dL])}.&#xD;
             Creatinine clearance for females = 0.85 x male value&#xD;
&#xD;
         13. Patients who had surgical therapy prior to referral will be eligible for randomization&#xD;
             to systemic chemotherapy administered in the adjuvant setting.&#xD;
&#xD;
         14. Patients who have overexpression of the her-2/neu oncogene are eligible for the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with N2 (clinical staging) or N3 (clinical staging) nodal disease,&#xD;
             inflammatory breast cancer, or metastatic disease are not eligible. This includes&#xD;
             patients with infraclavicular and/or supraclavicular lymph node involvement. Patients&#xD;
             with pN2a (metastasis in four to nine axillary lymph nodes) are eligible.&#xD;
&#xD;
          2. Patients with pN2b (metastasis in clinically apparent internal mammary lymph nodes in&#xD;
             the absence of axillary lymph node metastasis) are not eligible. Patients with T4&#xD;
             lesions in the neoadjuvant setting are not eligible. Patients with limited T4 lesions&#xD;
             in the adjuvant setting (for example, focal extension into the skin with negative&#xD;
             margins) are eligible.&#xD;
&#xD;
          3. Severe hypersensitivity reactions to agents formulated in either cremophor or&#xD;
             polysorbate 80 must be excluded. Patients with hypersensitivity reactions to any of&#xD;
             the study medications must be excluded.&#xD;
&#xD;
          4. Those patients with history of other malignancies will be excluded, except&#xD;
             non-melanoma skin cancer and non-invasive cervical cancer.&#xD;
&#xD;
          5. Patients with uncompensated congestive heart failure are not eligible. Patients with&#xD;
             myocardial infarction within the past 12 months are ineligible.&#xD;
&#xD;
          6. Patients who are pregnant or lactating are not eligible. Women of childbearing&#xD;
             potential must have a negative pregnancy test prior to initiation of chemotherapy.&#xD;
             Women of childbearing potential who will not use a reliable and appropriate&#xD;
             contraceptive method during the study are not eligible.&#xD;
&#xD;
          7. Patients who have had an organ allograft are ineligible.&#xD;
&#xD;
          8. Patients with serious concurrent infections are ineligible.&#xD;
&#xD;
          9. Sexually active male patients unwilling to practice contraception during the study are&#xD;
             ineligible.&#xD;
&#xD;
         10. Patients with pre-existing peripheral neuropathy &gt; grade 1.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aman U. Buzdar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center</description>
  </link>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>November 25, 2002</study_first_submitted>
  <study_first_submitted_qc>November 26, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2002</study_first_posted>
  <results_first_submitted>July 7, 2011</results_first_submitted>
  <results_first_submitted_qc>July 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 5, 2011</results_first_posted>
  <last_update_submitted>August 25, 2011</last_update_submitted>
  <last_update_submitted_qc>August 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Taxotere</keyword>
  <keyword>Taxol</keyword>
  <keyword>Xeloda</keyword>
  <keyword>Taxanes</keyword>
  <keyword>Operable Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period from November 20, 2002 to July 2, 2008. All recruitment done at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Planned accrual was 930 participants, only 601 were found eligible.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Weekly Paclitaxel (WP)</title>
          <description>Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="P2">
          <title>Docetaxel and Capecitabine (DX)</title>
          <description>Docetaxel + Capecitabine days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302"/>
                <participants group_id="P2" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="301"/>
                <participants group_id="P2" count="300"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>not eligible not invasive</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Weekly Paclitaxel (WP)</title>
          <description>Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="B2">
          <title>Docetaxel and Capecitabine (DX)</title>
          <description>Docetaxel + Capecitabine days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="302"/>
            <count group_id="B2" value="301"/>
            <count group_id="B3" value="603"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" lower_limit="42" upper_limit="57"/>
                    <measurement group_id="B2" value="50" lower_limit="42" upper_limit="57"/>
                    <measurement group_id="B3" value="50" lower_limit="42" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="603"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="302"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reoccurrence</title>
        <description>Percentage of participants where number with local recurrence, distant metastasis, or death of any cause at 50 months is divided by total number of participants and used as primary efficacy end point to compare paclitaxel to combination docetaxel and capecitabine in breast cancer treatment for preventing recurrence (return of cancer).</description>
        <time_frame>Median of 50 months</time_frame>
        <population>(WP Arm):301 included in the intent to treat analysis and 297 included in the safety analysis.&#xD;
(DX Arm):300 included in the intent to treat analysis and 292 included in the safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Weekly Paclitaxel (WP)</title>
            <description>Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles</description>
          </group>
          <group group_id="O2">
            <title>Docetaxel and Capecitabine (DX)</title>
            <description>Docetaxel + Capecitabine days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reoccurrence</title>
          <description>Percentage of participants where number with local recurrence, distant metastasis, or death of any cause at 50 months is divided by total number of participants and used as primary efficacy end point to compare paclitaxel to combination docetaxel and capecitabine in breast cancer treatment for preventing recurrence (return of cancer).</description>
          <population>(WP Arm):301 included in the intent to treat analysis and 297 included in the safety analysis.&#xD;
(DX Arm):300 included in the intent to treat analysis and 292 included in the safety analysis.</population>
          <units>participants</units>
          <param>Log Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" lower_limit="86.4" upper_limit="93.7"/>
                    <measurement group_id="O2" value="87.5" lower_limit="82.7" upper_limit="91.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Pathological Complete Response</title>
        <description>Safety of 2 Different Treatments determined by proportion of participants who achieved pathological complete response (pCR) between two different treatments; where pCR was defined as no histopathologic evidence of any residual invasive cancer cells in the breast and axillary lymph nodes.</description>
        <time_frame>7 Years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Treatment Effectiveness at Eradicating Tumor in the Breast and Lymph Nodes</title>
        <description>Effectiveness defined as proportion of patients who were able to have breast conserving surgery (BCS) after preoperative therapy compared to total number of participants.</description>
        <time_frame>7 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 years and 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Weekly Paclitaxel (WP)</title>
          <description>Weekly Paclitaxel for 12 weeks followed by Fluorouracil + Epirubicin + Cyclophosphamide (FEC) every 3 weeks for 4 cycles</description>
        </group>
        <group group_id="E2">
          <title>Docetaxel and Capecitabine (DX)</title>
          <description>Docetaxel + Capecitabine days 1-14 every 3 weeks for 4 cycles followed by FEC for 4 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="297"/>
                <counts group_id="E2" events="66" subjects_affected="66" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="297"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neurotoxicity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="297"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hand foot syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E2" events="54" subjects_affected="54" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="297" subjects_at_risk="301"/>
                <counts group_id="E2" subjects_affected="293" subjects_at_risk="300"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="297"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Neutropenic Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="64" subjects_affected="64" subjects_at_risk="297"/>
                <counts group_id="E2" events="131" subjects_affected="131" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E2" events="41" subjects_affected="41" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E2" events="118" subjects_affected="118" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="55" subjects_affected="55" subjects_at_risk="297"/>
                <counts group_id="E2" events="85" subjects_affected="85" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E2" events="50" subjects_affected="50" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="146" subjects_affected="146" subjects_at_risk="297"/>
                <counts group_id="E2" events="169" subjects_affected="169" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="297"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" events="109" subjects_affected="109" subjects_at_risk="297"/>
                <counts group_id="E2" events="137" subjects_affected="137" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neurotoxicity</sub_title>
                <counts group_id="E1" events="68" subjects_affected="68" subjects_at_risk="297"/>
                <counts group_id="E2" events="64" subjects_affected="64" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="239" subjects_affected="239" subjects_at_risk="297"/>
                <counts group_id="E2" events="266" subjects_affected="266" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Skin rash</sub_title>
                <counts group_id="E1" events="77" subjects_affected="77" subjects_at_risk="297"/>
                <counts group_id="E2" events="43" subjects_affected="43" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Hand Foot Syndrome</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="297"/>
                <counts group_id="E2" events="72" subjects_affected="72" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aman Buzdar, M.D./Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>agmadrig@mail.mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

